CJC-1295/Ipamorelin vs Sermorelin: Which Growth Hormone Peptide Is Right for You in 2026

Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed May 28, 2026.

The short answer

CJC-1295/Ipamorelin is a two-peptide stack. CJC-1295 is a modified GHRH analog with a 30-minute half-life. Ipamorelin is a selective ghrelin receptor agonist. Together they trigger a stronger, more sustained growth hormone pulse than either peptide alone.

Sermorelin is a single peptide: the 29-amino acid bioactive fragment of natural GHRH with a 10 to 15 minute half-life. It produces a brief, natural-feeling GH pulse.

Choose CJC-1295/Ipamorelin if you want the strongest GH response from a peptide stack and are targeting body composition, recovery, and sleep depth. Choose sermorelin if you are new to GH peptides, want the gentlest pulse, or are over 50 and prefer a more conservative starting protocol.

Both are compounded by Optimal Balance Pharmacy under a prescription written by an RxPepsDirect licensed provider in 28 states. CJC-1295/Ipamorelin runs $100 per 10mg+10mg vial; sermorelin runs $80 per 15mg vial. Both last 4 to 6 weeks at standard dosing.

What is CJC-1295/Ipamorelin?

CJC-1295/Ipamorelin is a compounded blend of two synergistic growth hormone secretagogues prescribed and dispensed in a single injectable vial.

CJC-1295 is a 30-amino acid modified analog of growth hormone-releasing hormone (GHRH). The original CJC-1295 was developed in the early 2000s with a drug affinity complex (DAC) modification that extended its half-life to roughly one week. The compounded CJC-1295 used in peptide telehealth today is the no-DAC version, which retains the stabilizing amino acid substitutions but drops the DAC modification, producing a half-life of roughly 30 minutes. The result is a GHRH analog that lasts about three times as long as sermorelin in circulation.

Ipamorelin is a pentapeptide ghrelin receptor agonist. Ghrelin is the body's endogenous hunger and GH-release hormone. Ipamorelin selectively binds the growth hormone secretagogue receptor (GHS-R1a) without significantly elevating cortisol, aldosterone, or prolactin, which are common off-target effects of older ghrelin agonists like GHRP-6 and hexarelin.

When paired, the two peptides hit two different pituitary pathways simultaneously. CJC-1295 stimulates GHRH receptors. Ipamorelin stimulates ghrelin receptors. The combined signal produces a larger, more sustained GH pulse than either peptide alone.

See the full CJC-1295/Ipamorelin product page for current pricing and the CJC-1295/Ipamorelin protocol guide for the complete dosing and protocol reference.

What is sermorelin?

Sermorelin is the 29-amino acid N-terminal fragment of natural GHRH. It is the smallest sequence of GHRH that retains full biological activity at the GHRH receptor. Anything shorter than 29 residues loses receptor affinity.

Sermorelin was FDA-approved as the branded drug Geref in 1997 for pediatric growth hormone deficiency and as a diagnostic agent. EMD Serono discontinued the branded product in 2008 for commercial reasons, not safety. Sermorelin remains an FDA-listed active ingredient eligible for compounding by 503A pharmacies under a patient-specific prescription.

The half-life is short: roughly 10 to 15 minutes in circulation. Sermorelin binds GHRH receptors on pituitary somatotrophs and triggers a brief, natural-feeling GH pulse. The short duration mimics the body's own pulsatile pattern more closely than longer-acting GHRH analogs.

See the sermorelin product page for current pricing and the sermorelin protocol guide for the full dosing reference.

Side-by-side comparison

Mechanism: one pathway vs two

Natural growth hormone release in the pituitary is controlled by two opposing hormonal signals: GHRH (which stimulates GH release) and somatostatin (which inhibits it). A third regulator, ghrelin, also stimulates GH release through a separate receptor.

Sermorelin hits one of these signals: GHRH. A sermorelin injection produces a short pulse of GHRH receptor stimulation, the pituitary releases GH, and somatostatin then shuts the response off within 30 to 60 minutes. The pulse is brief, natural, and self-limiting.

CJC-1295/Ipamorelin hits two signals. CJC-1295 stimulates GHRH receptors for roughly 30 minutes (longer than sermorelin). Ipamorelin simultaneously stimulates ghrelin receptors. The two signals are additive: the GH response is larger than either peptide produces alone, and the longer CJC-1295 duration extends the pulse window.

The result is a GH response that is meaningfully stronger than sermorelin at clinically used doses. For patients who want a more noticeable subjective effect (deeper sleep, faster recovery from training, more obvious body-composition shifts), CJC-1295/Ipamorelin delivers more per dose. For patients who want the gentlest possible GH support, sermorelin is closer to a single-signal physiologic mimic.

Dosing protocols

CJC-1295/Ipamorelin standard protocol

• Dose: 20 units subcutaneous injection (0.4mg CJC-1295 + 0.4mg Ipamorelin)
• Frequency: 5 nights per week, typically Monday through Friday
• Timing: 30 to 60 minutes before bed, on an empty stomach (food blunts the GH response)
• Cycling: Most providers run continuous protocols with periodic bloodwork. Some clinicians cycle 5-on / 2-off weekly or 8-on / 2-off in 10-week blocks
• Vial duration: 10mg+10mg vial lasts roughly 5 weeks at standard dosing

Sermorelin standard protocol

• Dose: 20 units subcutaneous injection (0.6mg sermorelin)
• Frequency: 5 nights per week, Monday through Friday
• Timing: 30 to 60 minutes before bed, on an empty stomach
• Cycling: Continuous protocols are typical; sermorelin's short half-life means the pulse is naturally self-limiting and tachyphylaxis is less of a concern
• Vial duration: 15mg vial lasts roughly 5 weeks at standard dosing

What the evidence actually shows

The randomized controlled trial base for both peptides is modest compared to FDA-approved synthetic HGH. Most published data come from short trials in specific populations (pediatric GHD, HIV-associated lipodystrophy, age-related GH decline) or from secondary endpoints in trials with different primary outcomes.

What is well-established: both peptides reliably raise serum GH and IGF-1 in healthy adults at clinically used doses. Sermorelin was used as a diagnostic agent precisely because its GH-releasing effect is reproducible. CJC-1295/Ipamorelin produces larger IGF-1 increases than sermorelin at equivalent frequency.

What is reasonable to infer: body composition, recovery, and sleep depth improvements over 8 to 16 weeks are consistent with the known effects of restoring pulsatile GH release in adults with age-related decline. The clinical magnitude is generally smaller than what supraphysiologic HGH produces, which is the point: GH secretagogues preserve the body's own feedback loop rather than overriding it.

What is overstated by marketing: dramatic anti-aging claims, large lean-mass gains in trained athletes, claims of GH levels matching elite-athlete profiles. Neither peptide produces supraphysiologic GH levels at therapeutic doses. The effect is restoration of pulsatile release, not amplification beyond physiologic.

Side effects compared

Both peptides share most of their side-effect profile because they trigger the body's own GH release through the pituitary rather than supplying exogenous synthetic HGH.

Common to both: injection-site flushing or itching, mild water retention in the first 2 to 4 weeks, occasional tingling in hands or feet (peripheral neuropathy from mild fluid shifts), vivid dreams or improved dream recall in the first week.

More common with CJC-1295/Ipamorelin: increased appetite (the Ipamorelin component activates ghrelin receptors, which is the same pathway that drives hunger), mild fasting glucose elevation in patients with insulin resistance, occasional headache in the first week.

Specific to neither: the carpal tunnel, joint aches, and edema that are characteristic of supraphysiologic HGH are uncommon at GH-secretagogue doses because the GH pulse magnitude stays within physiologic range.

Contraindications for both: active malignancy, pituitary tumor, severe diabetic retinopathy, pregnancy or breastfeeding. RxPepsDirect providers screen for these on intake.

Cost comparison

Both peptides are priced at 503A pharmacy wholesale through RxPepsDirect. There is no membership fee, no subscription, no markup. The $39 provider review covers the prescription; you pay the pharmacy directly for the medication.

The pricing gap exists because RxPepsDirect does not mark up the pharmacy product. Subscription clinics and concierge practices bundle the medication, provider time, and program management into a monthly fee. The compounded product is the same in most cases. See the full peptide telehealth comparison.

Who should choose which

Choose CJC-1295/Ipamorelin if

• You want the strongest GH response from a peptide stack
• Your primary goals are body composition (lean mass gain, fat redistribution) and recovery from training
• You want deeper, more obvious sleep improvement
• You have stable fasting glucose and no active appetite issues
• You have used sermorelin before and want a stronger effect, or you are starting fresh and want maximum effect per dose

Choose sermorelin if

• You are new to peptide therapy and want the gentlest GH support available
• You are over 50 and prefer a conservative starting protocol
• You have appetite control concerns or active weight loss goals
• You have borderline fasting glucose or want the most conservative metabolic profile
• You want the longest FDA history in the peptide class

Consider Sermorelin/Ipamorelin if

RxPepsDirect also offers a Sermorelin/Ipamorelin combination ($100 per 15mg+18mg vial) for patients who want the sermorelin half-life paired with the ghrelin-agonist additive effect. It sits between sermorelin alone and CJC-1295/Ipamorelin on the pulse magnitude spectrum.

How to get a prescription

Both peptides require a prescription from a licensed provider in your state.

1. Choose your peptide on the muscle growth catalog and add it to your protocol.
2. Complete the medical intake. Pay the $39 provider review.
3. An RxPepsDirect provider (Dr. Jonathan Snipes, MD or Kim Callender, FNP-BC) reviews your intake within 24 to 48 hours and approves the appropriate protocol.
4. The prescription is sent to Optimal Balance Pharmacy. They compound the product, ship pre-reconstituted, FedEx overnight in a reusable cooled travel case.
5. Refills are per vial with no auto-billing. Re-request when you need the next one.

Related comparisons

For more peptide comparisons in the growth hormone class:

• Tesamorelin vs sermorelin covers the comparison between the strongest GHRH analog (tesamorelin, the only FDA-approved drug in the class) and sermorelin
• Tesamorelin buyer's guide covers the Egrifta-vs-compounded comparison and pricing
• The peptide therapy pillar guide covers the full overview of how peptide therapy works
• Compounded vs research-grade peptides explains why a prescription pathway matters